Manuscripts and Publications

2020
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.
Burkes RM, Ceppe AS, Couper DJ, Comellas AP, J Wells M, Peters SP, Criner GJ, Kanner RE, Paine R, Christenson SA et al..  2020.  Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Chronic Obstr Pulm Dis. 7(4):370-381.
Gillenwater LA, Pratte KA, Hobbs BD, Cho MH, Zhuang Y, Halper-Stromberg E, Cruickshank-Quinn C, Reisdorph N, Petrache I, Labaki WW et al..  2020.  Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules.. Netw Syst Med. 3(1):159-181.
Strand M, Austin E, Moll M, Pratte KA, Regan EA, Hayden LP, Bhatt SP, Boriek AM, Casaburi R, Silverman EK et al..  2020.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.. Chronic Obstr Pulm Dis. 7(4):346-361.
2019
Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, R Barr G, Bleecker ER et al..  2019.  An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.. J Clin Invest. 129(1):169-181.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Halper-Stromberg E, Gillenwater L, Cruickshank-Quinn C, O'Neal WKay, Reisdorph N, Petrache I, Zhuang Y, Labaki WW, Curtis JL, Wells J et al..  2019.  Bronchoalveolar Lavage Fluid from COPD Patients Reveals More Compounds Associated with Disease than Matched Plasma.. Metabolites. 9(8)
Chin AT, Rylance J, Makumbirofa S, Meffert S, Vu T, Clayton J, Mason P, Woodruff P, Metcalfe J.  2019.  Chronic lung disease in adult recurrent tuberculosis survivors in Zimbabwe: a cohort study.. Int J Tuberc Lung Dis. 23(2):203-211.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Gu B-H, Choi JC, Shen YH, Song L-Z, Scheurer ME, Luong A, Rodriguez A, Woodruff P, Koth L, Corry DB et al..  2019.  Elastin-Specific Autoimmunity in Smokers With Thoracic Aortic Aneurysm and Dissection is Independent of Chronic Obstructive Pulmonary Disease.. J Am Heart Assoc. 8(8):e011671.
Oelsner EC, Ortega VE, Smith BM, Nguyen JN, Manichaikul AW, Hoffman EA, Guo X, Taylor KD, Woodruff PG, Couper DJ et al..  2019.  A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography.. Am J Respir Crit Care Med. 200(6):721-731.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, Lee CHyun, R Barr G, Bleecker E, Cooper CB et al..  2019.  Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS).. Respir Res. 20(1):153.
J Wells M, Xing D, Viera L, Burkes RM, Wu Y, Bhatt SP, Dransfield MT, Couper DJ, O'Neal W, Hoffman EA et al..  2019.  The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS.. Respir Res. 20(1):254.
Arjomandi M, Zeng S, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB et al..  2019.  Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.. Eur Respir J. 54(4)
J Wells M, Arenberg DA, Barjaktarevic I, Bhatt SP, Bowler RP, Christenson SA, Couper DJ, Dransfield MT, Han MK, Hoffman EA et al..  2019.  Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy.. Ann Am Thorac Soc. 16(4):439-446.
Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, R Barr G, Comellas AP, Hansel NN, Cooper CB et al..  2019.  Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.. Sci Rep. 9(1):11367.
Bin Cho H, Chae KJu, Jin GYong, Choi J, Lin CLong, Hoffman EA, Wenzel SE, Castro M, Fain SB, Jarjour NN et al..  2019.  Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers.. Korean J Radiol. 20(7):1236-1245.
Garudadri S, Woodruff PG, Han MK, Curtis JL, R Barr G, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G et al..  2019.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.. Chest. 155(5):908-917.
2018
Martinez CH, Li SX, Hirzel AJ, Stolberg VR, Alexis NE, R Barr G, Bleecker ER, Carretta EE, Christenson SA, Cooper CB et al..  2018.  Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort.. J Allergy Clin Immunol. 141(1):429-432.
Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, Woo J, J Wells M, Labaki WW, Doerschuk CM et al..  2018.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS.. Ann Am Thorac Soc. 15(6):710-717.
Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, Criner G, Galbán CJ, Ross BD, Hoffman EA et al..  2018.  Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.. Am J Respir Crit Care Med. 198(2):265-267.
Fawzy A, Putcha N, Paulin LM, Aaron CP, Labaki WW, Han MK, Wise RA, Kanner RE, Bowler RP, R Barr G et al..  2018.  Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.. Respir Res. 19(1):20.
Bhatt SP, Nath HP, Kim Y-I, Ramachandran R, Watts JR, Terry NLJ, Sonavane S, Deshmane SP, Woodruff PG, Oelsner EC et al..  2018.  Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort.. Respir Res. 19(1):257.
J Wells M, Parker MM, Oster RA, Bowler RP, Dransfield MT, Bhatt SP, Cho MH, Kim V, Curtis JL, Martinez FJ et al..  2018.  Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene.. JCI Insight. 3(22)

Pages